Research ExplorerPublicationsInduction therapy with rabbit antithymocyte globulin versus ...

Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation

Standard

Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation : a health economic analysis from a German perspective. / Cremaschi, Liana; von Versen, Regina; Benzing, Thomas; Wiesener, Michael; Zink, Nikolai; Milkovich, Gary; Paivanas, Thomas; Gallagher, Meghan; Thaiss, Friedrich.

In: TRANSPL INT, Vol. 30, No. 10, 10.2017, p. 1011-1019.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Cremaschi, L, von Versen, R, Benzing, T, Wiesener, M, Zink, N, Milkovich, G, Paivanas, T, Gallagher, M & Thaiss, F 2017, 'Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective', TRANSPL INT, vol. 30, no. 10, pp. 1011-1019. https://doi.org/10.1111/tri.12991

APA

Cremaschi, L., von Versen, R., Benzing, T., Wiesener, M., Zink, N., Milkovich, G., Paivanas, T., Gallagher, M., & Thaiss, F. (2017). Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective. TRANSPL INT, 30(10), 1011-1019. https://doi.org/10.1111/tri.12991

Vancouver

Cremaschi L, von Versen R, Benzing T, Wiesener M, Zink N, Milkovich G et al. Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective. TRANSPL INT. 2017 Oct;30(10):1011-1019. https://doi.org/10.1111/tri.12991

Bibtex

@article{ae00987f15c443719300e4dc9b225404,
title = "Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective",
abstract = "A health economic analysis was undertaken based on the 1-year database from a randomized study of rabbit anti-human thymocyte immunoglobulin (rATG) versus basiliximab, in kidney transplantation using resource utilization data and cost estimates from three German hospitals. A three-state Markov model was applied to estimate cost-effectiveness to 10 years post-transplant. Total mean treatment cost per patient to year 1 post-transplant was €62 075 vs. €59 767 for rATG versus basiliximab (P < 0.01). rATG therapy was associated with similar treatment costs to basiliximab by year 2, and a predicted cumulative treatment cost saving of €4 259 under rATG versus basiliximab by year 10 post-transplant. The mean number of quality-adjusted life years (QALYs) per patient by year 1 was 0.809 vs. 0.802 in the rATG and basiliximab cohorts, respectively (P = 0.38), with cumulative QALYs of 6.161 and 6.065 per patient by year 10. By year 2, the cumulative cost per QALY was slightly lower under rATG (€35 378) than basiliximab (€35 885), progressing to a saving of €1 041 under rATG for the cumulative cost per QALY by year 10. In conclusion, this model indicates that rATG induction provides a modest increase in QALYs with lower long-term costs than basiliximab in deceased-donor high-risk kidney transplant patients.",
keywords = "Animals, Antibodies, Monoclonal, Antilymphocyte Serum, Basiliximab, Humans, Immunosuppressive Agents, Induction Chemotherapy, Kidney Transplantation, Middle Aged, Quality-Adjusted Life Years, Rabbits, Recombinant Fusion Proteins, Comparative Study, Journal Article, Randomized Controlled Trial",
author = "Liana Cremaschi and {von Versen}, Regina and Thomas Benzing and Michael Wiesener and Nikolai Zink and Gary Milkovich and Thomas Paivanas and Meghan Gallagher and Friedrich Thaiss",
note = "{\textcopyright} 2017 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.",
year = "2017",
month = oct,
doi = "10.1111/tri.12991",
language = "English",
volume = "30",
pages = "1011--1019",
journal = "TRANSPL INT",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation

T2 - a health economic analysis from a German perspective

AU - Cremaschi, Liana

AU - von Versen, Regina

AU - Benzing, Thomas

AU - Wiesener, Michael

AU - Zink, Nikolai

AU - Milkovich, Gary

AU - Paivanas, Thomas

AU - Gallagher, Meghan

AU - Thaiss, Friedrich

N1 - © 2017 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.

PY - 2017/10

Y1 - 2017/10

N2 - A health economic analysis was undertaken based on the 1-year database from a randomized study of rabbit anti-human thymocyte immunoglobulin (rATG) versus basiliximab, in kidney transplantation using resource utilization data and cost estimates from three German hospitals. A three-state Markov model was applied to estimate cost-effectiveness to 10 years post-transplant. Total mean treatment cost per patient to year 1 post-transplant was €62 075 vs. €59 767 for rATG versus basiliximab (P < 0.01). rATG therapy was associated with similar treatment costs to basiliximab by year 2, and a predicted cumulative treatment cost saving of €4 259 under rATG versus basiliximab by year 10 post-transplant. The mean number of quality-adjusted life years (QALYs) per patient by year 1 was 0.809 vs. 0.802 in the rATG and basiliximab cohorts, respectively (P = 0.38), with cumulative QALYs of 6.161 and 6.065 per patient by year 10. By year 2, the cumulative cost per QALY was slightly lower under rATG (€35 378) than basiliximab (€35 885), progressing to a saving of €1 041 under rATG for the cumulative cost per QALY by year 10. In conclusion, this model indicates that rATG induction provides a modest increase in QALYs with lower long-term costs than basiliximab in deceased-donor high-risk kidney transplant patients.

AB - A health economic analysis was undertaken based on the 1-year database from a randomized study of rabbit anti-human thymocyte immunoglobulin (rATG) versus basiliximab, in kidney transplantation using resource utilization data and cost estimates from three German hospitals. A three-state Markov model was applied to estimate cost-effectiveness to 10 years post-transplant. Total mean treatment cost per patient to year 1 post-transplant was €62 075 vs. €59 767 for rATG versus basiliximab (P < 0.01). rATG therapy was associated with similar treatment costs to basiliximab by year 2, and a predicted cumulative treatment cost saving of €4 259 under rATG versus basiliximab by year 10 post-transplant. The mean number of quality-adjusted life years (QALYs) per patient by year 1 was 0.809 vs. 0.802 in the rATG and basiliximab cohorts, respectively (P = 0.38), with cumulative QALYs of 6.161 and 6.065 per patient by year 10. By year 2, the cumulative cost per QALY was slightly lower under rATG (€35 378) than basiliximab (€35 885), progressing to a saving of €1 041 under rATG for the cumulative cost per QALY by year 10. In conclusion, this model indicates that rATG induction provides a modest increase in QALYs with lower long-term costs than basiliximab in deceased-donor high-risk kidney transplant patients.

KW - Animals

KW - Antibodies, Monoclonal

KW - Antilymphocyte Serum

KW - Basiliximab

KW - Humans

KW - Immunosuppressive Agents

KW - Induction Chemotherapy

KW - Kidney Transplantation

KW - Middle Aged

KW - Quality-Adjusted Life Years

KW - Rabbits

KW - Recombinant Fusion Proteins

KW - Comparative Study

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1111/tri.12991

DO - 10.1111/tri.12991

M3 - SCORING: Journal article

C2 - 28556488

VL - 30

SP - 1011

EP - 1019

JO - TRANSPL INT

JF - TRANSPL INT

SN - 0934-0874

IS - 10

ER -